Introduction：Basic information about CAS 1445993-26-9|Mivebresib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Mivebresib |
|---|
| CAS Number | 1445993-26-9 | Molecular Weight | 459.466 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | 608.9±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C22H19F2N3O4S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 322.0±34.3 °C |
|---|
Names
| Name | N-[4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide |
|---|
| Synonym | More Synonyms |
|---|
Mivebresib BiologicalActivity
| Description | Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM. |
|---|
| Related Catalog | Signaling Pathways >>Epigenetics >>Epigenetic Reader DomainResearch Areas >>Cancer |
|---|
| Target | IC50: 1.5 nM (BET)[1] |
|---|
| In Vitro | Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1]. |
|---|
| References | [1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Boiling Point | 608.9±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C22H19F2N3O4S |
|---|
| Molecular Weight | 459.466 |
|---|
| Flash Point | 322.0±34.3 °C |
|---|
| Exact Mass | 459.106445 |
|---|
| LogP | 3.91 |
|---|
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
|---|
| Index of Refraction | 1.647 |
|---|
| InChIKey | RDONXGFGWSSFMY-UHFFFAOYSA-N |
|---|
| SMILES | CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(-c2cn(C)c(=O)c3[nH]ccc23)c1 |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| N-[4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide |
| N-[4-(2,4-Difluorphenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethansulfonamid |
| N-[4-(2,4-Difluorophénoxy)-3-(6-méthyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phényl]éthanesulfonamide |
| Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]- |
| Mivebresib |
| ABBV-075 |
